SCHEMBL6181576

SCHEMBL6181576

CC(=O)OC1CCNC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL435813 1.00
SCHEMBL436562 1.00
Hydrochloric Acid SCHEMBL27799701 0.98 CHRM2 (0.37)
Hydrochloric Acid SCHEMBL27702575 0.98 CHRM2 (0.37)
SCHEMBL1489698 0.88 SLC6A1 (0.44)
SCHEMBL21003949 0.88 SLC6A1 (0.44)
Trifluoroacetic Acid SCHEMBL20576082 0.88 SLC6A1 (0.33)
SCHEMBL5640241 0.86 CHRM2 (0.40)
SCHEMBL1490076 0.86 GABRA1 (0.41)
Hydrochloric Acid SCHEMBL27675051 0.86 SLC6A1 (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12441714-B2 Pyrrolidine compounds ELI LILLY AND COMPANY (US) 2025-10-14 US disclosed
US-12358868-B2 Chemical derivatives and methods for synthesizing and compounding chemical derivatives related to capsaicin palmitate and capsaicin prodrugs CHORDA PHARMA, INC. (US) 2025-07-15 US disclosed
US-12312316-B2 Compounds and methods for the targeted degradation of androgen receptor ARVINAS OPERATIONS, INC. (US) 2025-05-27 US disclosed
US-20250101028-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BEIGENE, LTD. (KY) 2025-03-27 US disclosed
CN-119504751-A Bifunctional chimeric heterocyclic compound for targeting and degrading androgen receptor and application thereof 海创药业股份有限公司 2025-02-25 CN disclosed
US-20250059221-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-02-20 US disclosed
US-12077555-B2 STAT degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-09-03 US disclosed
WO-2024103178-A1 ANISOMYCIN ANALOGS AND USES THEREOF Université de Montréal (CA) 2024-05-23 WO disclosed
CN-117642392-A Preparation and application of compounds with immunoregulation function 上海轶诺药业有限公司 2024-03-01 CN disclosed
US-20230406816-A1 CHEMICAL DERIVATIVES AND METHODS FOR SYNTHESIZING AND COMPOUNDING CHEMICAL DERIVATIVES RELATED TO CAPSAICIN PALMITATE AND CAPSAICIN PRODRUGS CHORDA PHARMA INC (US) 2023-12-21 US disclosed
US-5550257-A TREATING CENTRAL CHOLINERGIC DYSFUNCTION AMERICAN CYANAMID COMPANY (US) 1996-08-27 US disclosed
US-5451685-A MANUFACTURING PHARMACEUTICALS AMERICAN CYANAMID COMPANY (US) 1995-09-19 US disclosed
EP-0381984-B1 3- or 4-substituted oxotremorine derivatives AMERICAN CYANAMID CO (US) 1995-04-19 EP disclosed
US-5356885-A Cholinergic agents; administering for treatment of diseases of the central nervous system AMERICAN CYANAMID COMPANY (US) 1994-10-18 US disclosed
US-5346910-A CHOLINERGIC AGENTS AMERICAN CYANAMID COMPANY (US) 1994-09-13 US disclosed
EP-0510333-A1 Substituted oxotremorine derivatives AMERICAN CYANAMID COMPANY (US) 1992-10-28 EP disclosed
US-5089518-A 3- or 4-substituted oxotremorine derivatives and a method of treating cholinergic dysfunction therewith AMERICAN CYANAMID COMPANY (US) 1992-02-18 US disclosed
US-4952600-A TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM AMERICAN CYANAMID COMPANY (US) 1990-08-28 US disclosed
EP-0381984-A1 3- or 4-substituted oxotremorine derivatives AMERICAN CYANAMID COMPANY (US) 1990-08-16 EP disclosed
US-4937235-A Anticholinergic agents AMERICAN CYANAMID COMPANY (US) 1990-06-26 US disclosed